Neurocrine Biosciences Inc (NBIX) is a publicly traded Healthcare sector company. As of September 2, 2026, NBIX trades at $157.94 with a market cap of $15.93B and a P/E ratio of 22.36. NBIX moved +0.61% today. Year to date, NBIX is +12.23%; over the trailing twelve months it is +15.93%. Its 52-week range spans $84.23 to $186.12. Analyst consensus is strong buy with an average price target of $210.60. Rallies surfaces NBIX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
26 analysts cover NBIX: 0 strong buy, 23 buy, 3 hold, 0 sell, and 0 strong sell. The consensus rating is strong buy. The average price target is $210.60.
| Metric | Value |
|---|---|
| Price | $157.94 |
| Market Cap | $15.93B |
| P/E Ratio | 22.36 |
| EPS | $7.05 |
| Dividend Yield | 0.00% |
| 52-Week High | $186.12 |
| 52-Week Low | $84.23 |
| Volume | 836.30K |
| Avg Volume | 0 |
| Revenue (TTM) | $3.37B |
| Net Income | $705.50M |
| Gross Margin | 0.00% |
26 analysts cover NBIX: 0 strong buy, 23 buy, 3 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $210.60.